The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
Official Title: Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) Chemotherapy Plus Cisplatin (or Carboplatin) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
Study ID: NCT02906150
Brief Summary: Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Azienda Sanitaria Locale Frosinone, Frosinone, , Italy
Istituto Nazionale dei Tumori, Milan, , Italy
Roma_Campus Bio-Medico, Rome, , Italy
Roma_Gemelli, Rome, , Italy
Roma_Regina Apostolorum, Rome, , Italy
Roma_Tor Vergata, Rome, , Italy
Sant'Andrea Hospital, Rome, , Italy
Presidio Sanitario San Camillo, Torino, , Italy